Climb Bio Inc
CLYMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Climb Bio Inc focuses on Biotechnology services and products. Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. Valued at $727.2M, CLYM is a small-cap name in its sector. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Market Cap
$727.2M
Beta
0.07
P/E (TTM)
—
P/E (Fwd)
-11.32
EPS (TTM)
$-0.77
EPS (Fwd)
$-1.12
ROE
-30.9%
ROA
-21.3%
Cash
$109.6M
Total Debt
$479,000
Free CF
-$34.7M
52W Change
741.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $109.6M in cash comfortably exceeding the $479K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$34.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -30.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
CLYM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Climb Bio Inc's trajectory.